Aug 05, 2021
Atossa Therapeutics to Present at the BTIG Virtual Biotechnology Conference on August 9-10, 2021
Jul 07, 2021
Atossa Therapeutics Receives Regulatory Approval To Open Clinical Study of AT-H201 in Australia
Jun 16, 2021
Atossa Therapeutics Set to Be Included in the Russell 2000 and Russell 3000 Indexes
Jun 11, 2021
Atossa Therapeutics Receives Approval from Swedish Regulators to Initiate Phase 2 Clinical Study of Oral Endoxifen to Reduce Mammographic Breast Density
Jun 09, 2021
Atossa Therapeutics Announces Final Data from Phase 2 Endoxifen Breast Cancer Study Primary Endpoint Met: 65.1% Reduction in Biomarker Ki-67; Secondary Endpoint Met: Endoxifen Safe and Well Tolerated
Jun 07, 2021
Atossa Therapeutics to Release Final Data from Phase 2 Study of Endoxifen Administered to Breast Cancer Patients Prior to Surgery at a Webinar at 8 am Pacific Time on June 9, 2021
May 14, 2021
Atossa Therapeutics Announces First Quarter 2021 Financial Results and Provides Corporate Update
May 14, 2021
Atossa Therapeutics to Participate at the Investor Summit Conference and Present to Investors on May 18, 2021
May 11, 2021
Atossa Therapeutics Urges Shareholders to Vote on Proposals Ahead of its Annual Stockholder Meeting May 14, 2021 at 1:00 PM Pacific Time
Apr 30, 2021
Atossa Therapeutics CEO Dr. Steven Quay to Participate in Panel Discussion at Cello Health's Cancer Progress Virtual Conference on May 6, 2021
1
2
3
4
5
6
7
8
9
<<
<
>
>>
Privacy
